Drug Profile
PYX 202 - Pyxis Oncology
Alternative Names: anti-DLK1 ADC; DLK1-MMAE; LCB-67; LCB14-15XX - Legochem Biosciences/Y-Biologics; MMAE-anti-DLK1; PYX-202 - Pyxis OncologyLatest Information Update: 29 Sep 2022
Price :
$50
*
At a glance
- Originator LegoChem Biosciences
- Developer LegoChem Biosciences; Pyxis Oncology
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours